We read with interest the recent article published by Bonanad et al.1
The topic of this consensus document is valuable and important; however, we encountered ambiguities and questions in one part of the article.
In table 3 of the article, in the description of the adverse cardiovascular effects of drugs investigated for COVID-19 treatment, the authors state that correction of hyperkalemia and hypermagnesemia is vital, while correction of hypokalemia and hypomagnesemia may be particularly imperative since low serum levels of potassium and magnesium enhances the possibility of QT prolongation.2
Hypokalemia, probably by modification of ion potassium channel function, can prolong the QT interval in a manner that results in heterogeneity and dispersion of repolarization. Similarly, hypomagnesemia is a well-established predisposing risk factor for torsade de pointes.3 In addition, potassium deficiency seems to be common in severe coronavirus disease 2019 (COVID-19).4 Several findings indicated that serum potassium should be maintained in the high normal range (4.5-5.0 mmol/L), although more evidence is needed to support this practice.3,5